세계의 세포배양용 배지, 혈청, 시약 시장 : 예측(-2030년)

Market Overview

The media sera and reagents- cell culture market is projected to reach USD 18,800 Million by 2030 at 10.5% CAGR during the review period.

Cell culture is the way cells develop under controlled conditions outside the common habitat. In cell culture, the states of every cell type are unique, yet the fake climate comprises of a medium or reagents that give supplements to the cell.

The ascent of popularity for biotechnological and biopharmaceutical items, developing instances of expanding persistent illnesses, and the developing interest for treating utilizing cell culture techniques will drive the market's development. The higher interests in innovative work in biotechnology will emphatically impel the market's development. Numerous advancements in the field of rDNA innovation and drugs will animate the market's development. The capital venture for a Cell culture office is costly, which might obstruct the development of the market.

America possesses the biggest market because of extraordinary interest in innovative work in the biotech and pharma enterprises. The monetary circumstances for innovative work are considerably higher. The developing mindfulness among individuals and the presence of central members in this region will add to the development of the market.

Market Segmentation

Based on application, type, and end-user, the global media sera and reagents-cell culture market is divided into segments. The type segment is further divided into medium, sera, and reagents.

The media segment includes chemically defined media, serum-free media, protein-free media, traditional media, and others. The market based on sera is classified into fetal bovine serum, newborn calf serum, and various types of serum.

In terms of reagents the global sera, media, and cell culture market is further divided into antibiotics, biological detergents, biological buffers, cell viability kits and reagents, and others.

In terms of application, the global market is categorized into drug development, cancer research, toxicity testing, virology, vaccine development, and others based on applications.

The market is divided into pathology labs, academic institutions, research laboratories, and others by end users.

Regional analysis

America dominates the biggest market because of its immense interest in innovative work in biotech and pharma ventures and its monetary circumstances for innovative work. Rising mindfulness among individuals and the presence of many central members in this region have likewise contributed to the development of the market.

Europe is expected to become the second largest market for media sera and reagents-cell culture market followed by Asia Pacific. Because of the accessibility of assets for innovative work exercises and developing accentuation on research for treating sicknesses. Asia Pacific shows the quickest development in this market because of an expansion in commonness of transferable illnesses. For the most part, India and China are beginning use in innovative work areas of medical care space.

Key players

The major players in the media, sera and reagents-cell culture market are PAN biotech (Germany), Hi-media Laboratories (India), Sigma Aldrich (US), Thermofisher Scientific (US), Merck KGaA (Germany), Biowest (France), General Electric company (US), VWR International, Lonza AG (Switzerland), PromoCell GmbH, and others.

TABLE OF CONTENTS

TABLE OF CONTENTS

1 REPORT PROLOGUE

2 MARKET INTRODUCTION

• 2.1 INTRODUCTION
• 2.2 SCOPE OF STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 ASSUMPTIONS & LIMITATIONS
  • 2.4.1 ASSUMPTIONS
  • 2.4.2 LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 RESEARCH PROCESS
• 3.2 PRIMARY RESEARCH
• 3.3 SECONDARY RESEARCH

4 MARKET DYNAMICS

• 4.1 DRIVERS
• 4.2 RESTRAINTS

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF RIVALRY
• 5.2 SUPPLY CHAIN ANALYSIS

6. GLOBAL MEDIA SERA AND REAGENTS- CELL CULTURE, BY TYPE

• 6.1 MEDIA
  • 6.1.1 CHEMICALLY DEFINED MEDIA
  • 6.1.2 SERUM-FREE MEDIA
  • 6.1.3 PROTEIN FREE MEDIA
  • 6.1.4 CLASSICAL MEDIA
  • 6.1.5 OTHERS
• 6.2 SERA
  • 6.2.1 FETAL BOVINE SERUM
  • 6.2.2 NEW-BORN CALF SERUM
  • 6.2.3 OTHERS
• 6.3 REAGENTS
  • 6.3.1 ANTIBIOTICS
  • 6.3.2 BIOLOGICAL DETERGENTS
  • 6.3.3 BIOLOGICAL BUFFERS
  • 6.3.4 CELL VIABILITY KITS AND REAGENTS
  • 6.3.5 OTHERS

7. GLOBAL MEDIA SERA AND REAGENTS- CELL CULTURE MARKET, BY APPLICATION

• 7.1 CANCER RESEARCH
• 7.2 VIROLOGY
• 7.3 TOXICITY TESTING
• 7.4 VACCINE PRODUCTION
• 7.5 DRUG DEVELOPMENT
• 7.6 OTHERS

8. GLOBAL MEDIA SERA AND REAGENTS- CELL CULTURE MARKET, BY END USERS

• 8.1 RESEARCH LABORATORIES
• 8.2 ACADEMIC INSTITUTIONS
• 8.3 PATHOLOGY LABS
• 8.4 OTHER

9. GLOBAL MEDIA SERA AND REAGENTS- CELL CULTURE MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 AMERICA
  • 9.2.1 NORTH AMERICA
    • 9.2.1.1 US
    • 9.2.1.2 CANADA
  • 9.2.2 SOUTH AMERICA
• 9.3 EUROPE
  • 9.3.1 WESTERN EUROPE
    • 9.3.1.1 GERMANY
    • 9.3.1.2 UK
    • 9.3.1.3 FRANCE
    • 9.3.1.4 ITALY
    • 9.3.1.5 SPAIN
    • 9.3.1.6 REST OF WESTERN EUROPE
  • 9.3.2 EASTERN EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 JAPAN
  • 9.4.2 CHINA
  • 9.4.3 INDIA
  • 9.4.4 AUSTRALIA
  • 9.4.5 REPUBLIC OF KOREA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 MIDDLE EAST & AFRICA
  • 9.5.1 UNITED ARAB EMIRATES
  • 9.5.2 SAUDI ARABIA
  • 9.5.3 OMAN
  • 9.5.4 KUWAIT
  • 9.5.5 QATAR
  • 9.5.6 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 COST OF PRODUCTS
• 10.2 PRODUCTION CAPACITY OF MAJOR PLAYERS

11 COMPANY PROFILE

• 11.1 PAN BIOTECH
  • 11.1.1 OVERVIEW
  • 11.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.1.3 FINANCIAL UPDATES
  • 11.1.4 KEY DEVELOPMENTS
• 11.2 MERCK KGAA
  • 11.2.1 OVERVIEW
  • 11.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.2.3 FINANCIAL UPDATES
  • 11.2.4 KEY DEVELOPMENTS
• 11.3 SIGMA ALDRICH
  • 11.3.1 OVERVIEW
  • 11.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.3.3 FINANCIAL UPDATES
  • 11.3.4 KEY DEVELOPMENT
• 11.4 PFIZER INC
  • 11.4.1 OVERVIEW
  • 11.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.4.3 FINANCIAL UPDATES
  • 11.4.4 KEY DEVELOPMENT
• 11.5 THERMOFISHER SCIENTIFIC
  • 11.5.1 OVERVIEW
  • 11.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.5.3 FINANCIAL UPDATES
  • 11.5.4 KEY DEVELOPMENTS
• 11.6 GENERAL ELECTRIC COMPANY
  • 11.6.1 OVERVIEW
  • 11.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.6.3 FINANCIAL UPDATES
  • 11.6.4 KEY DEVELOPMENTS
• 11.7 BIOWEST
  • 11.7.1 OVERVIEW
  • 11.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.7.3 FINANCIAL UPDATES
  • 11.7.4 KEY DEVELOPMENTS
• 11.8 LONZA AG
  • 11.8.1 OVERVIEW
  • 11.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.8.3 FINANCIAL UPDATES
  • 11.8.4 KEY DEVELOPMENTS
• 11.9 PROMOCELL GMBH
  • 11.9.1 OVERVIEW
  • 11.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
  • 11.9.3 FINANCIAL UPDATES
  • 11.9.4 KEY DEVELOPMENTS
• 11.9 OTHERS

12 CONCLUSION

• 12.1 KEY FINDINGS
  • 12.1.1 FROM CEO'S VIEWPOINT
  • 12.1.2 UNMET NEEDS OF THE MARKET
• 12.2 KEY COMPANIES TO WATCH
• 12.3 PREDICTION OF LIFE SCIENCE INDUSTRY

13 APPENDIX